首页 查尔斯河(usCRL)-基本信息

查尔斯河(usCRL)-基本信息

日报更新时间:

周报更新时间:04-11 03:39

行情信息

今开价:322.08

最高价:323.89

成交量:384364.0

昨收价:320.37

最低价:316.37

最新价:323.38

行情图标
概要信息

中文名称:查尔斯河


英文名称:Charles River Laboratories


行业:医疗


简介:Charles River Laboratories International, Inc.在1947年开始运作,从那时起,它已经历了几次业务结构的改变


电话:1-781-2226000


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

查尔斯河实验室国际公司是一家在全球提供早期阶段的药物发现和临床前开发服务合同公司,公司分为3个部门来运作:研究模型和服务(Research Models and Services,RMS)、发现和安全评估(Discovery and Safety Assessment,DSA)、制造支持(Manufacturing Support)。 研究模型和服务部门:生产和销售的研究模式菌株主要是基因和微生物学定义为有目地饲养的、研究人员使用的大鼠和小鼠,提供一系列的服务以帮助客户在支持研究和筛查临床候选药物研究模式的使用,包括基因工程模型和服务,内包解决方案,以及研究动物诊断服务。 发现和安全评估部门:通过临床前药物投递和准备好安全性评估的治疗候选人提供早期和体内发现服务给药目标识别所用,还有安全评估服务,其中包括生物分析,药代动力学,药物代谢,毒理学,病理学服务。 制造支持部门:提供以体外方式给无菌和非无菌生物制药的常规性和快速的品管测试以及消费产品,还提供由制药和生物技术公司外包生物制剂和设施的专业测试,和提供无特定病原体动物肥沃鸡蛋和鸡禽用于以活病毒制造的禽类疫苗服务。Charles River Laboratories International公司服务对象有制药和生物技术公司,合同研究组织,农业,化工等企业,生命科学与兽医学公司,合同制造企业,医疗器械企业,诊断和其他商业团体,医院,学术机构和政府机构。查尔斯河实验室国际Charles River Laboratories International(CRL)历史百科: 2003年10月,Charles River Laboratories 与英国专业从事临床研究和临床前测试的公司 Inveresk 合并; 2009年末,Charles River出售其位于Edinburgh的临床服务部门(Clinical Services Division)给Quotient Bioresearch company; 2010年,Charles River Laboratories试图收购中国WuXi PharmaTech,然而却遭到了包括Relational Investors、JANA Partners、Neuberger Berman的大股东反对而不得不作罢;代理咨询公司RiskMetrics也建议股东投反对票; 2015年7月,查尔斯河实验室国际以2.12亿美元收购Celsis International; 2016年1月,查尔斯河实验室国际以5.85亿美金收购WIL Research; 2016年6月,Charles River Laboratories宣布收购Blue Stream Laboratories。

交易日期 交易人 职位 类型 交易份额 价格
2019-05-28 Barbo (William D) Officer Sell 2 124.95
2019-05-28 Barbo (William D) Officer Sell 51 124.98
2019-05-28 Barbo (William D) Officer Sell 100 125.12
2019-05-28 Barbo (William D) Officer Sell 120 125.76
2019-05-28 Barbo (William D) Officer Sell 104 124.96
2019-05-28 Barbo (William D) Officer Sell 300 125.53
2019-05-28 Barbo (William D) Officer Sell 96 126.19
2019-05-28 Barbo (William D) Officer Sell 200 125.03
2019-05-28 Barbo (William D) Officer Sell 50 125.26
2019-05-28 Barbo (William D) Officer Sell 4 126.09
2019-05-28 Barbo (William D) Officer Sell 100 125.18
2019-05-28 Barbo (William D) Officer Buy 2158 76.67
2019-05-28 Barbo (William D) Officer Sell 100 125.70
2019-05-28 Barbo (William D) Officer Sell 21 126.00
2019-05-28 Barbo (William D) Officer Sell 30 125.84
2019-05-28 Barbo (William D) Officer Sell 13 126.15
2019-05-28 Barbo (William D) Officer Sell 100 124.90
2019-05-28 Barbo (William D) Officer Sell 20 125.88
2019-05-28 Barbo (William D) Officer Sell 397 124.89
2019-05-28 Barbo (William D) Officer Sell 100 125.74
2019-05-28 Barbo (William D) Officer Sell 50 125.89
2019-05-28 Barbo (William D) Officer Sell 44 124.88
2019-05-28 Barbo (William D) Officer Sell 100 125.29
2019-05-28 Barbo (William D) Officer Sell 100 126.08
2019-05-28 Barbo (William D) Officer Sell 498 124.94

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Lord, Abbett & Co LLC 678997 1.39% -169429 -19.97% 2019-03-31
Fidelity Management and Research Company 1611010 3.30% -120512 -6.96% 2019-03-31
FMR Inc 1673497 3.43% -133212 -7.37% 2019-03-31
Fidelity Management & Research Company 1831352 3.75% -29360 -1.58% 2019-07-31
Renaissance Technologies Corp 1885700 3.87% 8591 0.46% 2019-03-31
AQR Capital Management LLC 2082761 4.27% 317001 17.95% 2019-03-31
BlackRock Fund Advisors 2560448 5.25% -78518 -2.98% 2019-07-31
BlackRock Inc 4587801 9.41% 57789 1.28% 2019-03-31
Vanguard Group Inc 5218583 10.70% -64256 -1.22% 2019-03-31
Vanguard Investments Australia Ltd 1324208 2.71% 179 0.01% 2019-07-31
State Street Corporation 1168175 2.40% 27580 2.42% 2019-03-31
First Trust Advisors L.P. 1098166 2.25% -1233 -0.11% 2019-03-31
Wells Fargo Funds Management LLC 688391 1.41% -30929 -4.30% 2019-07-31
Congress Asset Management Company, LLP 751848 1.54% -16686 -2.17% 2019-03-31
Goldman Sachs Group Inc 801645 1.64% 46412 6.15% 2019-03-31
Brown Investment Advisory Incorporated 846080 1.74% 48076 6.02% 2019-03-31
Ariel Investments, LLC 846442 1.74% -141729 -14.34% 2019-03-31
Brown Advisory Holdings Inc 847304 1.74% 48076 6.02% 2019-03-31
TimesSquare Capital Management, LLC 863575 1.77% -163475 -15.92% 2019-03-31
Wells Fargo & Co 1045887 2.15% -426992 -28.99% 2019-03-31
BlackRock Asset Management Canada Ltd 5684092 11.66% 880 0.02% 2019-05-31
Geode Capital Management, LLC 915058 1.88% 486407 113.47% 2018-12-31
Fidelity International Ltd 1429840 2.96% -317681 -18.18% 2018-09-30
Acadian Asset Management LLC 926330 1.92% 822185 789.46% 2018-09-30
Wells Capital Management Inc. 1183988 2.46% -60217 -4.84% 2018-09-30
BlackRock Institutional Trust Company NA 1606826 3.34% 5001 0.31% 2018-06-30
Bank of New York Mellon Corp 784349 1.63% -32702 -4.00% 2018-06-30
Mackenzie Investments 719731 1.50% -351447 -32.81% 2018-03-31
William Blair Investment Management, LLC 1671909 3.48% -36614 -2.14% 2018-06-30
State Street Corp 1203332 2.51% -47333 -3.78% 2018-06-30
Congress Asset Management Co 827441 1.72% -3748 -0.45% 2018-06-30
Channing Capital Management, LLC 688502 1.43% -13081 -1.86% 2018-06-30
Neuberger Berman LLC 657997 1.37% -24232 -3.55% 2018-06-30
Van Berkom and Associates Inc 617391 1.29% 4250 0.69% 2018-06-30
State Street Global Markets, LLC 553043 1.15% -4900 -0.88% 2018-07-31
Fidelity Institutional Asset Management 1853321 3.87% -94700 -4.86% 2018-03-31
Goldman, Sachs & Co. 942021 1.97% 4370 0.47% 2018-03-31
Alyeska Investment Group, L.P. 617804 1.29% 617804 -- 2018-03-31
Dimensional Fund Advisors, Inc. 537745 1.13% 757 0.14% 2017-12-31
D. E. Shaw & Co LP 641674 1.36% 107447 20.11% 2017-09-30
Morgan Stanley & Co International PLC 489714 1.03% -366000 -42.77% 2017-09-30
Millennium Management LLC 1228039 2.58% 208111 20.40% 2017-06-30
PRIMECAP Management Company 909660 1.92% -61000 -6.28% 2016-09-30
Wellington Management Company LLP 837390 1.77% -43604 -4.95% 2016-09-30
OppenheimerFunds Inc 536859 1.13% 457265 574.50% 2016-09-30
Merrill Lynch & Co Inc 527023 1.11% -211869 -28.67% 2016-09-30
Wellington Management Group,LLP 3162714 3.00% 245742878 0.10% 1999-11-30
The Vanguard Group,Inc. 3851778 3.00% 299283151 0.10% 1999-11-30
Black Rock,Inc. 4831806 3.00% 375431326 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Ariel Fund 262706 0.54% -- -- 2019-06-30
iShares Core S&P Mid-Cap ETF 1433027 2.94% 2760 0.19% 2019-07-30
Vanguard Total Stock Market Index Fund 1312707 2.69% 246 0.02% 2019-06-30
Vanguard Small Cap Index 1247333 2.56% -10667 -0.85% 2019-06-30
First Trust NYSE Arca Biotech Fund 695502 1.42% -1676 -0.24% 2019-07-31
Wells Fargo Special Mid Cap Value Fund 685300 1.40% -- -- 2019-06-30
Vanguard Extended Market Index Fund 667495 1.37% 2140 0.32% 2019-06-30
SPDR 555171 1.14% 1602 0.29% 2019-06-30
Fidelity Small Cap America Fund 434720 0.89% -25000 -5.44% 2019-03-31
Vanguard Strategic Equity Fund 408720 0.84% -44030 -9.73% 2019-03-31
Vanguard Small Cap Value Index Fund 388587 0.80% -11569 -2.89% 2019-06-30
Brown Advisory Small-Cap Growth Fund 268135 0.55% -- -- 2019-06-30
State Street S&P Mid Cap Index Fund 298283 0.61% 1900 0.64% 2019-07-31
Fidelity 300000 0.61% -- -- 2019-04-30
Lord Abbett Value Opportunities Fund 329794 0.68% -- -- 2019-05-31
Vanguard Small Cap Growth Index Fund 356741 0.73% -587 -0.16% 2019-06-30
Vanguard Capital Opportunity Fund 363000 0.74% -- -- 2019-03-31
T. Rowe Price QM US Small-Cap Gr Eq Fd 379200 0.78% -- -- 2019-06-30
iShares S&P US Mid-Cap ETF 1404819 2.88% -- -- 2019-05-30
iShares S&P US Mid-Cap ETF (CAD-Hedged) 1404819 2.88% -- -- 2019-05-30
iShares Core S&P US Total Market ETF 1404819 2.88% -- -- 2019-05-30
iShares Core MSCI AllCntry Wld exCan ETF 1405365 2.88% -- -- 2019-05-23
Vanguard Small Cap Index Fund 1259910 2.58% 9164 0.73% 2019-04-30
iShares S&P Mid-Cap 400 Growth ETF 235225 0.48% 1289 0.55% 2019-03-29
Fidelity Advisor 261700 0.54% -38300 -12.77% 2018-11-30
First Trust Health Care AlphaDEX 231900 0.48% -- -- 2019-03-28
AQR Long-Short Equity Fund 235225 0.49% -557 -0.24% 2018-09-30
OH Putnam Fidelity Adv Small-Cap 261700 0.54% -38300 -12.77% 2018-11-30
Fidelity American Equity Fund 348701 0.72% -- -- 2018-09-30
Ariel Appreciation Fund 305780 0.64% -58900 -16.15% 2018-09-30
Vanguard Mid Cap Growth 252500 0.52% -26700 -9.56% 2018-06-30
Carillon Eagle Mid Cap Growth Fund 250242 0.52% 44905 21.87% 2017-12-31
Lord Abbett Value Opportunities A 449894 0.94% 66600 17.38% 2018-07-31
Fidelity Spartan 216561 0.45% 2109 0.98% 2018-07-31
William Blair Small-Mid Cap Gr I 219954 0.46% -92900 -29.69% 2018-07-31
Congress Mid Cap Growth Institutional 220000 0.46% -- -- 2018-07-31
Vanguard Total Stock Mkt Idx 1197244 2.49% 1334 0.11% 2018-07-31
Wells Fargo Special Mid Cap Value Inst 1054900 2.20% -- -- 2018-07-31
Vanguard Small Cap Value Index Inv 757417 1.58% 8034 1.07% 2018-07-31
Vanguard Extended Market Idx Inv 635398 1.32% -- -- 2018-07-31
First Trust NYSE Arca Biotech ETF 598097 1.32% -- -- 2018-09-13
Vanguard Strategic Equity Inv 554833 1.16% 9288 1.70% 2018-06-30
iShares S&P Mid-Cap 400 Growth 424277 0.92% 4193 1.00% 2018-09-12
Vanguard Capital Opportunity Inv 383000 0.80% -- -- 2018-06-30
Ariel Appreciation Investor 364680 0.76% -- -- 2018-06-30
Ariel Fund Investor 358606 0.75% -36095 -9.14% 2018-06-30
T. Rowe Price QM US Small-Cap Growth Eq 337200 0.70% 43000 14.62% 2018-06-30
Vanguard Mid Cap Growth Inv 252500 0.53% -26700 -9.56% 2018-06-30
AQR Long-Short Equity I 235782 0.49% 235782 -- 2018-06-30
Victory Integrity Small-Cap Value A 209673 0.44% 7800 3.86% 2018-06-30
Brown Advisory Small-Cap Growth Inv 208819 0.44% 30708 17.24% 2018-05-31
Invesco Select Companies A 205310 0.43% -- -- 2018-03-31
Eagle Mid Cap Growth A 250242 0.53% 44905 21.87% 2017-12-31
Neuberger Berman Intrinsic Value Instl 225371 0.48% -- -- 2017-12-31
AST Prudential Growth Allocation Port 229000 0.48% -- -- 2017-12-31
Hodges Small Cap Retail 360000 0.76% -10000 -2.70% 2016-09-30
PRIMECAP Odyssey Aggressive Growth 372000 0.79% -19660 -5.02% 2016-12-31
Vanguard Global Equity Inv 220887 0.47% -3012 -1.35% 2016-09-30
CREF Stock R1 224545 0.47% 18383 8.92% 2016-12-31
Strategic Advisers 213859 0.45% -83110 -27.99% 2016-11-30
iShares Core S&P Mid-Cap (AU) 815958 2.00% 1100 0.10% 2015-11-19
Fidelity Small Cap America Class 676320 1.40% 40000 6.30% 2015-06-30
Fidelity Canadian Balanced Class 662786 1.40% -- -- 2015-06-30
Invesco Select Companies Fund 662655 1.40% -49146 -6.90% 2015-09-30
ZIL Blackrock Global Fds Wld Health Sci 506800 1.10% -- -- 2015-07-31
Fidelity Canadian Growth Company Class 506736 1.10% -159600 -23.90% 2015-06-30
PrimeCap Odyssey Aggressive Growth Fund 496660 1.10% -95340 -16.10% 2015-09-30
BlackRock Health Sciences Opps Port 875500 1.90% -- -- 2015-10-31

C. Richard Reese C. Richard Reese is Chief Executive officer at Iron Mountain Information Management, Inc. and President at Iron Mountain. He is also on the board of Charles River Laboratories International, Inc. Mr. Reese previously was Executive Chairman at Iron Mountain, Inc. and President & Director at PRISM International. He received an MBA from Harvard University and an undergraduate degree and a graduate degree from Clemson University.
George E. Massaro George E. Massaro is on the board of Charles River Laboratories International, Inc. and Huron Consulting Group, Inc. (former Non-Executive Chairman). In his past career Mr. Massaro held the position of Managing Partner at Arthur Andersen LLP, Chief Operating Officer of Huron Consulting Services LLC and Trustee at Mount Auburn Hospital. He received an MBA from Babson College and an undergraduate degree from Bentley University.
Robert J. Bertolini Robert J. Bertolini is on the board of Bristol-Myers Squibb Co., Charles River Laboratories International, Inc., Actelion Pharmaceuticals Ltd. and Idorsia Ltd. In his past career he held the position of President & Chief Financial Officer of Bausch & Lomb Holdings, Inc., President & Chief Financial Officer for Bausch + Lomb, Inc., Chief Financial Officer & Executive Vice President for Schering-Plough Corp. and Partner at PricewaterhouseCoopers LLP. Robert J. Bertolini received an undergraduate degree from Rutgers State University of New Jersey.
Deborah Turner Kochevar Deborah Turner Kochevar is on the board of Charles River Laboratories International, Inc. and Elanco Animal Health, Inc. and Senior Vice President for Tufts University. In the past Dr. Kochevar held the position of President for Association of American Veterinary Medical College, Chairman-Education Council at American Veterinary Medical Association, Member of College of Veterinary Medicine & Biomedical Sciences, President-Veterinary Clinical Pharmacology at The American College and Dean at Cummings School of Veterinary Medicine. She received a doctorate from The American College, an undergraduate degree from Rice University, a doctorate from Texas A&M University and a doctorate from The University of Texas Southwestern Medical Center.
Michael Gunnar Knell Michael Gunnar Knell holds the position of Chief Accounting Officer & Senior Vice President at Charles River Laboratories International, Inc., Treasurer of Bruker Detection Corp. and Chief Accounting Officer for Bruker Daltonics, Inc. In the past Mr. Knell held the position of Chief Accounting Officer & Vice President-Finance at Bruker Corp. and Partner at Ernst & Young LLP. Mr. Knell received an undergraduate degree from State University of New York at Buffalo.
Victoria L. Creamer Currently, Victoria L. Creamer holds the position of Chief People Officer & Senior Vice President at Charles River Laboratories International, Inc. In her past career Ms. Creamer occupied the position of Vice President-Global Compensation & Recognition at International Business Machines Corp. and Chief Human Resources Officer & Senior VP of ITT, Inc. and Senior Vice President-Human Resources of ITT Corp. (a subsidiary of ITT, Inc.). Ms. Creamer received an undergraduate degree from Hartwick College and a graduate degree from Fordham University.
Richard F. Wallman Richard F. Wallman is on the board of Roper Technologies, Inc. and 8 other companies. In the past Mr. Wallman occupied the position of Chief Financial Officer & Senior Vice President at Honeywell International, Inc. and Chief Financial Officer & Senior Vice President of Honeywell International LLC (a subsidiary of Honeywell International, Inc.), Controller of International Business Machines Corp. and Principal at Chrysler Corp. Richard F. Wallman received an undergraduate degree from Vanderbilt University and an MBA from The University of Chicago Booth School of Business.
George M. Milne Currently, George M. Milne occupies the position of Chairman of Aurinia Pharmaceuticals, Inc. He is also Venture Partner at Radius Ventures LLC and on the board of 6 other companies. In his past career he was President-Central Research at Pfizer Inc. and Chairman for Melinta Subsidiary Corp. Dr. Milne received an undergraduate degree from Yale University and a doctorate from Massachusetts Institute of Technology.
James C. Foster Presently, James C. Foster occupies the position of Chairman, President & Chief Executive Officer of Charles River Laboratories International, Inc. He is also on the board of Cell Signaling Technology, Inc. and MIT Sloan School of Management and Chairman of Institute of Contemporary Art, Member of Massachusetts Bar Association and Member of American Bar Association. In his past career James C. Foster occupied the position of President, General Counsel & VP-Administration at Charles River Biotechnical Services, Inc., Vice President for Smith Barney, Inc., Manager-Private Money at RiverSource Investments LLC and Member-Visits Committee at The Museum of Fine Arts. He received an undergraduate degree from Lake Forest College, a graduate degree from Massachusetts Institute of Technology and a graduate degree from Boston University.
David Patrick Johst Mr. David P. Johst is a Chairman at Charles River Discovery Research Services Finland Oy, a Secretary & Director at Charles River Laboratories Edinburgh Ltd. and a Secretary & Chief Administrative Officer at Charles River Laboratories International, Inc. He is on the Board of Directors at Charles River Laboratories Edinburgh Ltd., Argenta Discovery 2009 Ltd., BioFocus DPI (Holdings) Ltd., Charles River Discovery Research Services UK Ltd., Charles River Laboratories Holdings Ltd., Charles River UK Ltd. and Mount Ida College. Mr. Johst was previously employed as an Attorney-Corporate Department by Hale & Dorr LLP. He received his undergraduate degree from Dartmouth College, a graduate degree from Harvard Law School and an MBA from Northeastern University.
Stephen D. Chubb Stephen D. Chubb is a businessperson who has been at the head of 5 different companies. Mr. Chubb is on the board of Charles River Laboratories International, Inc., Allegro Diagnostics Corp. (former President, Chief Executive Officer & Director), Codevax, Inc. and Amylyx Pharmaceuticals, Inc. He previously was Chairman & Chief Executive Officer of Matritech, Inc., President & Chief Executive Officer at T Cell Sciences, Inc., President & Chief Executive Officer at Jazz Pharmaceuticals (EUSA Pharma USA), Inc. and Co-Chairman for Mount Auburn Hospital.
J�0�1�0�9rg M. Geller Dr. J�0�1�0�9rg M. Geller is Executive VP-Global Productivity & Efficiency at Charles River Laboratories International, Inc. He received his doctorate degree from the University of Giessen and a doctorate degree from the University of Hannover.
Jean-Paul Mangeolle Jean-Paul Mangeolle is on the board of Charles River Laboratories International, Inc., Gelest, Inc. and Avantor Performance Materials, Inc. and President-Bioprocess Division & Vice President at EMD Millipore Corp. In his past career Mr. Mangeolle occupied the position of Executive VP-Process Solutions Business Unit at Merck KGaA and President-Bioprocess Division at Millipore SAS (a subsidiary of Merck KGaA), President for Phenomenex, Inc., President of AB Sciex LLC and Vice President-Operations at Mykrolis Corp. Mr. Mangeolle received a graduate degree from the University of Montpellier and an undergraduate degree from Universit�0�1�0�8 de Chamb�0�1�0�8ry.
John C. Ho John C. Ho is Chief Strategy Officer & SVP-Corporate Strategy at Charles River Laboratories International, Inc. In his past career he held the position of Partner at McKinsey & Co., Inc., Senior Vice President-Corporate Strategy at Charles River Laboratories International, Inc., Partner at PRTM Management Consultants LLC and Partner at Accenture (California). He received an undergraduate degree from Massachusetts Institute of Technology, a doctorate from The Warren Alpert Medical School and an MBA from Tuck School of Business at Dartmouth.
Brian Bathgate Brian Bathgate is on the board of Charles River Laboratories Edinburgh Ltd. and Senior Vice President-European Safety Assessment at Charles River Laboratories International, Inc. Dr. Bathgate previously held the position of Group EVP & President-Preclinical Europe Operation at Inveresk Research Group, Inc. Brian Bathgate received an undergraduate degree from the University of Glasgow and a doctorate from The University of Nottingham.
John C. Ho John C. Ho is Chief Strategy Officer & SVP-Corporate Strategy at Charles River Laboratories International, Inc. In his past career he held the position of Partner at McKinsey & Co., Inc., Senior Vice President-Corporate Strategy at Charles River Laboratories International, Inc., Partner at PRTM Management Consultants LLC and Partner at Accenture (California). He received an undergraduate degree from Massachusetts Institute of Technology, a doctorate from The Warren Alpert Medical School and an MBA from Tuck School of Business at Dartmouth.
Martin MacKay Martin MacKay is an American businessperson who founded Rallybio LLC and who has been the head of 6 different companies. Dr. MacKay holds the position of Chief Executive Officer & Director at Rallybio LLC and Chief Executive Officer of Calyx Group Plc. He is also on the board of Charles River Laboratories International, Inc. and Novo Nordisk A. He previously was Operations Director at Dun & Bradstreet Corp., Global Head-Research & Development at Alexion Pharmaceuticals, Inc., Senior Vice President-Worldwide Development at Pfizer Inc. and President for Pfizer Global Research & Development (a subsidiary of Pfizer Inc.), Vice President-International at VeriSign, Inc., Principal at PeopleSoft USA, Inc., President-Research & Development at AstraZeneca Plc, Principal at Beecham Pharmaceuticals (UK), Chief Executive Officer & Director at Neverfail, Inc., Chief Executive Officer at Vecta Software Corp. Ltd., Chief Executive Officer & Director at Neverfail Group Ltd., Head-Drug Preformulation & Delivery at BASF Performance Products Plc, Principal at Accenture LLC, Head-Molecular & Cell Biology at CRI Worldwide LLC, Director-Business Development of NorthgateArinso, Inc. and Head-Drug Preformulation & Delivery at Ciba-Geigy Pharmaceuticals. He received an undergraduate degree from Heriot-Watt University and a doctorate from The University of Edinburgh.
David Ross Smith Mr. David R. Smith is a Chief Financial Officer & Executive Vice President at Charles River Laboratories International, Inc. He is on the Board of Directors at Celsis Group Ltd., Celsis International Ltd., Nastor Investments Ltd., Charles River Discovery Research Services Finland Oy, Charles River Laboratories Edinburgh Ltd., Argenta Discovery 2009 Ltd., BioFocus DPI (Holdings) Ltd., Celsis Ltd., Charles River Discovery Research Services UK Ltd., Charles River Laboratories Holdings Ltd. and Charles River UK Ltd. Mr. Smith was previously employed as a Chief Financial Officer by Cambridge University Hospitals NHS Foundation Trust, a Chief Executive Officer by Galapagos NV, a Chief Financial Officer by AstraZeneca AB, a Chief Financial Officer by AstraZeneca BV, a Chief Financial Officer by AstraZeneca Kft, and a Chief Financial Officer by AstraZeneca Plc. He received his undergraduate degree from the University of Leeds.
William D. Barbo Presently, William D. Barbo holds the position of Chief Commercial Officer & Executive VP of Charles River Laboratories International, Inc. Mr. Barbo received an undergraduate degree from Boston College, a graduate degree from the University of Massachusetts and an MBA from Northeastern University.
Foster T. Jordan Foster T. Jordan is Senior Vice President-Microbial Solutions at Charles River Laboratories International, Inc. In the past Mr. Jordan occupied the position of Director-Research & Development at Endosafe, Inc. and Director-Research & Development at Endosafe, Inc. He received an undergraduate degree from Wofford College.
Foster T. Jordan Foster T. Jordan is Senior Vice President-Microbial Solutions at Charles River Laboratories International, Inc. In the past Mr. Jordan occupied the position of Director-Research & Development at Endosafe, Inc. and Director-Research & Development at Endosafe, Inc. He received an undergraduate degree from Wofford College.
Matthew L. Daniel Currently, Matthew L. Daniel is SVP-Legal Compliance & Deputy General Counsel at Charles River Laboratories International, Inc. He received an undergraduate degree from Cornell University and a graduate degree from New York University School of Law.
Matthew L. Daniel Currently, Matthew L. Daniel is SVP-Legal Compliance & Deputy General Counsel at Charles River Laboratories International, Inc. He received an undergraduate degree from Cornell University and a graduate degree from New York University School of Law.
William D. Barbo Presently, William D. Barbo holds the position of Chief Commercial Officer & Executive VP of Charles River Laboratories International, Inc. Mr. Barbo received an undergraduate degree from Boston College, a graduate degree from the University of Massachusetts and an MBA from Northeastern University.
Colin Dunn Colin Dunn is on the board of Charles River Laboratories Holdings Ltd. and Senior VP, GM-Research Models & Services at Charles River Laboratories International, Inc. Dr. Dunn received an undergraduate degree from the University of Glasgow and a doctorate from the University of Strasbourg.
Birgit Girshick Ms. Birgit Girshick is an EVP-Discovery & Safety Assessment at Charles River Laboratories International, Inc. She is on the Board of Directors at Charles River Discovery Research Services Finland Oy, Argenta Discovery 2009 Ltd., BioFocus DPI (Holdings) Ltd. and Charles River Discovery Research Services UK Ltd. She received her undergraduate degree from Eastern Connecticut State University and an MBA from the University of Rhode Island.
Joseph W. LaPlume Joseph W. LaPlume is Executive VP-Corporate Development & Strategy at Charles River Laboratories International, Inc. He received a graduate degree and an MBA from Boston University and an undergraduate degree from Trinity College (Connecticut).
Shanna L. Cotti-Osmanski Presently, Shanna L. Cotti-Osmanski occupies the position of Chief Information Officer at Charles River Laboratories International, Inc. She received an undergraduate degree from The Pennsylvania State University.
Grace G. Lee Presently, Grace G. Lee occupies the position of Senior Vice President-Global Human Resources at Charles River Laboratories International, Inc. In the past Ms. Lee held the position of Senior Vice President-Global Human Resources at TTM Technologies, Inc. and Senior VP-Global Human Resources & Communications at Beckman Coulter, Inc. She received an undergraduate degree from the University of the Philippines and a graduate degree from the University of San Diego.
Gina Mullane Currently, Gina Mullane is Chief Marketing Officer & Senior Vice President for Charles River Laboratories International, Inc. Ms. Mullane received an undergraduate degree from the University of New Hampshire and an MBA from Bentley University.
Shannon M. Parisotto Shannon M. Parisotto occupies the position of Senior VP-Global Operations & Controller at Charles River Laboratories International, Inc. Ms. Parisotto received an undergraduate degree from the University of Nevada and an MBA from the University of Phoenix.
Barbara j. Patterson Currently, Barbara j. Patterson is Senior VP-Regulatory Affairs & Compliance at Charles River Laboratories International, Inc. In the past she was Senior Director-Regulatory Compliance at Primedica Corp. She received an undergraduate degree from The Pennsylvania State University.
Kristen M. Eisenhauer Currently, Kristen M. Eisenhauer holds the position of Senior Vice President-Client Services & Sales at Charles River Laboratories International, Inc. Ms. Eisenhauer received an undergraduate degree from the University of Nevada and an MBA from Suffolk University.
Todd Spencer Presently, Todd Spencer holds the position of Vice President-Investor Relations at Charles River Laboratories International, Inc.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐